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This work identifies the fragile-X-related protein
(FXR1) as a reciprocal regulator of HuR target tran-
scripts in vascular smooth muscle cells (VSMCs).
FXR1 was identified as an HuR-interacting protein
by liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS). The HuR-FXR1 interaction is abro-
gated in RNase-treated extracts, indicating that their
association is tethered by mRNAs. FXR1 expression
is induced in diseased but not normal arteries. siRNA
knockdown of FXR1 increases the abundance and
stability of inflammatory mRNAs, while overexpres-
sion of FXR1 reduces their abundance and stability.
Conditionedmedia from FXR1 siRNA-treated VSMCs
enhance activation of naive VSMCs. RNA EMSA and
RIP demonstrate that FXR1 interacts with an ARE
and an element in the 30 UTR of TNFa. FXR1 expres-
sion is increased in VSMCs challenged with the anti-
inflammatory cytokine IL-19, and FXR1 is required for
IL-19 reduction of HuR. This suggests that FXR1 is an
anti-inflammation responsive, HuR counter-regula-
tory protein that reduces abundance of pro-inflam-
matory transcripts.
INTRODUCTION
Despite nutritional modification and lipid-reducing medications,
atherosclerotic and other vascular syndromes account for 50%
of all mortality and is increasing in the developing world. The inju-
rious effects of pro-inflammatory cytokines resulting in vascular
smooth muscle cell (VSMC) activation and development of mul-
tiple vascular diseases are well described (Allahverdian et al.,
2014; Ross, 1999). Results from the recent CANTOS trial support
the preeminent role of inflammation in vascular disease (Weber
and von Hundelshausen, 2017). VSMCs respond to and synthe-
size pro-inflammatory immune modulators (Doran et al., 2008;
Hansson and Libby, 2006; Singer et al., 2004) and promulgate
the recruitment of leukocytes to the lesion (Hansson and Libby,1176 Cell Reports 24, 1176–1189, July 31, 2018 ª 2018 The Author(s
This is an open access article under the CC BY license (http://creative2006; Libby et al., 1997), leading to a localized vascular inflam-
matory lesion. In many vascular diseases, VSMCs migrate into
the intima, where they proliferate and synthesize cytokines and
matrix proteins leading to loss of lumen and subsequent tissue
ischemia. Resolution of inflammation is a dynamic and tightly
regulated process, and much attention has been aimed at iden-
tification of countervailing mechanisms that modulate inflamma-
tory processes (Fredman and Tabas, 2017; Libby et al., 2014).
A better understanding of countervailing mechanisms that
modulate inflammatory processes, and identification of proteins
and pathways that modulate the VSMC response to injury is key
to the development of therapeutics to combat multiple vascular
diseases.
The regulation of mRNA stability and translation are two levels
of post-transcriptional regulation that permit VSMCs to rapidly
respond to inflammatory stimuli (Barreau et al., 2006). AU-rich
elements (AREs) in the 30 UTR of mammalian mRNA appear to
be the target sequence for degradation or stabilization of
transcripts. Most of the transcripts targeted for rapid degrada-
tion encode key regulatory proteins involved in cell growth,
inflammation, and other responses to external stimuli (Bakheet
et al., 2001). Importantly, most inflammatory cytokines contain
conserved or semi-conserved AU-rich elements in their 30
UTR, imparting target specificity for a potential anti-inflamma-
tory modality (Peng et al., 1996). Controlling mRNA decay allows
the cell to fine-tune mRNA abundance and translation for rapid
adaptation to environmental conditions, especially inflammation
(Schoenberg and Maquat, 2012). An essential regulatory protein
involved in this process is human antigen R (HuR), a member of
the Elav protein family and one of the best characterized, ARE-
recognizing, RNA-binding proteins (RBPs) involved inmRNA sta-
bility and regulation of pro-inflammatory gene expression (Doller
et al., 2008; Palanisamy et al., 2012). While HuR is ubiquitously
expressed, it is activated in response to inflammatory signals
to stabilize inflammatory mediators (Doller et al., 2008; Palanis-
amy et al., 2012). Since most pro-inflammatory transcripts
contain AREs in their 30 UTR, this is a crucial and specific mech-
anism for the initiation and maintenance of the pro-inflammatory
phenotype observed in vascular diseases. The exact mecha-
nisms of HuR regulation have yet to be characterized; however,
they could represent key targets in regulating inflammation).
commons.org/licenses/by/4.0/).
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(Gallouzi and Steitz, 2001). Even though modulation of mRNA
stability has been posited as a possible therapeutic strategy
(Eberhardt et al., 2007), surprisingly, there is negligible literature
exploring the concept that it could be directly regulated or
possibly reduced by anti-inflammatory stimuli. We posit that
the regulation of HuR and other RBPs is a critical, and under-
studied, step in the regulation of vascular inflammation.
We previously reported that interleukin (IL)-19, an anti-inflam-
matory cytokine, reduced inflammatory transcript mRNA stabil-
ity in VSMCs (Cuneo et al., 2010) and reduced HuR abundance in
several cell types (Ellison et al., 2013). In this report, we identify
and characterize one protein, termed fragile X-related protein
(FXR1), a muscle-enhanced, autosomal homolog of the FMR
(fragile X mental retardation) neural protein, which interacts
with HuR in inflammatory, but not basal, conditions. We report
here that FXR1 expression is induced by IL-19 in VSMCs and
that modulation of FXR1 regulates ARE-containing transcripts
in VSMCs. RNA EMSA (electrophoretic mobility shift assay)
and RNA immunoprecipitation demonstrate that FXR1 interacts
with the canonical AREs and a previously uncharacterized
element in the 30 UTR of tumor necrosis factor alpha (TNFa.
This work implicates FXR1 as a previously unrecognized nega-
tive regulator of inflammation and suggests that IL-19 induction
of FXR1 expression is a negative compensatory, counter-regula-
tory mechanism used by VSMCs to respond to and resolve
inflammation.
RESULTS
HuR Interacts with FXR1
It is presumed that HuR activity is regulated by interacting pro-
teins (Doller et al., 2008; Gallouzi and Steitz, 2001; Pullmann
et al., 2005). Human vascular smooth muscle cells (hVSMCs)
were transfected with a FLAG-tagged HuR or FLAG-tagged
empty control vector and then starved for 48 hr in 0.1% fetal
bovine serum (FBS) before stimulation with TNFa. HuR pull-
down was followed by un-biased liquid chromatography-tan-
dem mass spectrometry (LC-MS/MS) to identify the proteins
that immunoprecipitated with HuR. HuR-interacting candidates
were identified by eliminating any protein with a raw peptide
count below ten (Table S1). Interacting proteins were also scru-
tinized in the Contaminant Repository for Affinity Purification
(CRAPome) database (Mellacheruvu et al., 2013) to determine
the occurrence of proteins in control experiments to eliminate
‘‘sticky proteins’’ that may non-specifically interact with HuR.Figure 1. FXR1 and HuR Interact
(A) Co-immunoprecipitation of endogenous FXR1 with HuR in unstimulated or TN
(B) hVSMCs transduced with adeno-GFP-control vector, FLAG-tagged adeno-
conjugated beads.
(C) The FXR1-HuR interaction increases in TNFa-stimulated conditions.
(D) FXR1-HuR interaction is mediated by mRNA. The addition of RNase A to the
(E) HuR and FXR1 co-localization in hVSMCs. HuR remained predominantly nu
stimulation with TNFa, HuR shuttled to the cytoplasm where it co-localized with
(F) High-resolution confocal microscopy of HuR-FXR1 interaction in the cytoplas
(G) FXR1 and HuR co-localize to stress granules. HVSMCs were untreated or stim
marker poly(A)-binding protein (PABP), FXR1, and HuR, and with DAPI, and were
Magnification is 6303 for (E) and (G) and 1,2603 for (F).
See also Tables S1 and S2.
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for Gene Ontology (GO) annotation. A number of interacting pro-
teins were identified; most were involved in various aspects
of mRNA processing (Table S2). The last row of Table S2 in-
cludes Elav1 (HuR), as it was the bait protein used to perform
LC-MS/MS, although nothing is known about HuR and the
FLAG-tag epitope according to the CRAPome database. FXR1
was chosen for further study because of the novelty of its inter-
action; because FXR1 expression is muscle enhanced (Garnon
et al., 2005; Mientjes et al., 2004); and because no literature ex-
ists on FXR1 inducibility by inflammatory stimuli or VSMC, mak-
ing FXR1 a particularly attractive target to study in the context of
vascular disease. Finally, similar to HuR, FXR1 is presumed to be
an RBP (Adinolfi et al., 1999). FXR1 exists in several isoforms in
mouse and is predicted to have three isoforms in human (Dube´
et al., 2000). We were only able to detect isoform 1 in human
VSMCs by western blot and transcript-specific qRT-PCR (data
not shown). Subsequent experiments utilized isoform 1 to ensure
that all domains were represented.
A series of immunoprecipitations were performed in order to
confirm the interaction between HuR and FXR1. First, we per-
formed a co-immunoprecipitation of endogenous FXR1 for
HuR in hVSMCs that were either serum starved or serum starved
and stimulated with TNFa for 8 hr (Figure 1A). We also overex-
pressed FXR1 using a FLAG-tagged adenovirus (adeno-FXR1
[AdFXR1]) and concurrently overexpressed HuR also using an
adenovirus (AdHuR) in hVSMCs and performed immunoprecipi-
tation using anti-FLAG-conjugated beads (Figure 1B). Next,
hVSMCs were treated as described, but after serum starvation,
they were stimulated with TNFa for 8 hr. Figure 1C shows that
the HuR/FXR1 interaction was enhanced in TNFa-stimulated
cells. Figure 1D shows that the FXR1-HuR interaction is abro-
gated by the addition of RNase A, suggesting that the interaction
we identified via proteomics may bemediated by RNA tethering.
The increased FXR1-HuR interaction observed in TNFa-stimu-
lated VSMCsmay be due to an increase in transcripts that harbor
both FXR1 and HuR binding elements.
We next used confocal microscopy to determine HuR and
FXR1 localization under basal and inflammatory conditions in
hVSMCs. HuR nucleocytoplasmic shuttling has been reported
(Wu et al., 2016), and consistent with the literature, in TNFa-sti-
mulated VSMCs, HuR translocated from the nucleus to the
cytoplasm. FXR1 remained predominantly cytoplasmic in both
unstimulated and stimulated conditions. Interestingly, HuR
and FXR1 co-localized in the cytoplasm following 8-hr TNFaFa-stimulated VSMCs. IP, immunoprecipitation; IB, immunoblot.
FXR1, and HuR adenovirus, followed by immunoprecipitation by anti-FLAG-
immunoprecipitation reaction disrupted TNFa-driven FXR1-HuR interaction.
clear, while FXR1 localized to the cytoplasm in unstimulated VSMCs. Upon
FXR1.
m of TNFa-stimulated hVSMCs.
ulated with 20 mM clotrimazole for 45 min and then stained for stress granule
imaged using confocal microscopy to determine co-localization.
Figure 2. FXR1 Protein Expression in
Vascular Injury and Disease Models
(A) FXR1 expression in ligated murine carotid artery.
Mouse carotid arteries were harvested 28 days
after ligation, and immunohistochemistry was per-
formed. FXR1 primarily stains in the neointima (n.i.),
but not the media (m.) in the ligated artery.
(B) FXR1 expression in mouse atherosclerotic pla-
que. Cross-section from an LDLR/ mouse aorta
fed an HFD for 12 weeks to develop atherosclerotic
plaque. VSMCs in plaque and smooth muscle cell
cap are enriched for FXR1 expression.
(C) FXR1 expression in normal human coronary
artery from a non-failing heart.
(D) FXR1 expression in myleofibroid atherosclerotic
plaque from a failing human artery. FXR1 expression
is enriched in myleofibroid VSMCs in the plaque as
compared to healthy human control artery.
(E) Fluorescent co-staining of fibro-atherosclerotic
cap from human atherosclerotic plaque using anti-
body to SMC-actin and FXR1. See also Figure S1 for
normal mouse artery and negative controls for
immunohistochemistry.
Magnification is 2003 for all panels. The arrows
point to areas of enhanced FXR1 expression in (A)
VSMCs of the neointima or in (B) VSMC of the cap of
the atherosclerotic plaque.
See also Figure S1.stimulation, which is consistent with literature showing HuR nu-
cleocytoplasmic translocation upon inflammatory stimuli (Fig-
ures 1E and 1F). RNA processing often occurs in phase-dense
structures that form in the cytoplasm of eukaryotic cells in
response to environmental stresses. The composition of stress
granules suggests that regulation of labile ARE-containing in-
flammatory transcripts could be occurring there. To further asso-
ciate a relationship between FXR1 and HuR in RNA processing,
we used immunostaining and confocal microscopy to co-
localize HuR and FXR1 within punctate stress granules in
hVSMCs. Clotrimazole was used to induce stress granule forma-
tion, and poly(A)-binding protein (PABP) was used as a marker
for stress granules (Kedersha et al., 2008). Figure 1G shows
that hVSMCs stimulated with 20 mM clotrimazole demonstrated
well-defined, punctate co-localization of FXR1 and HuR in stress
granules, which further suggests a role for FXR1 along with HuR
in RNA processing in VSMCs.
FXR1 Expression Is Induced in Diseased VSMCs
There is no literature describing FXR1 induction in VSMCs or
models of vascular injury. We examined FXR1 expression in
mouse and human atherosclerotic and restenotic tissue and de-
tected inducible FXR1 expression in VSMCs in multiple models
of vascular injury. Figure 2A indicates that FXR1 expression is
increased in neointimal, compared with medial, VSMCs in theCellcarotid artery from ligated mice. Similarly,
FXR1 expression is increased in VSMCs
in atherosclerotic plaque and cap, but
much lower in non-diseased medial
VSMCs in the aortic arch from LDLR/
mice fed an atherogenic diet (Figure 2B).FXR1 expression is negligible in normal, non-diseased arteries
from these mice (Figures S1A and S1B). Importantly, FXR1
expression is barely detectible in a coronary artery from a non-
failing human heart, but expression is enhanced in myofibrous
atherosclerotic plaque from a human coronary artery (Figures
2C and D). Figure 2E shows dual-color immunohistochemistry
indicating that FXR1 expression co-localizes in plaque SMCs
in the human coronary artery. Together, these data suggest
that FXR1 induction is a VSMC response to inflammatory stimuli
in vivo.
FXR1 Regulates Abundance and mRNA Stability of Pro-
inflammatory mRNA and Protein
Literature on FXR1 function is inconsistent and appears to be
cell type specific. To more definitively link FXR1 function with
vascular inflammation, we transfected hVSMCs with FXR1-spe-
cific small interfering RNA (siRNA) and then stimulated the cells
with TNFa. Knockdown of FXR1 resulted in a dramatic and sig-
nificant increase in the abundance of inflammatory transcripts
in hVSMCs (IL-1 b, ICAM1, and MCP-1 are shown as examples).
Interestingly, these transcripts have been previously shown to be
stabilized by HuR in other cell types (Aguado et al., 2015; Chen
et al., 2006; Krishnamurthy et al., 2010; Wu et al., 2016) (Fig-
ure 3A). Correspondingly, Figure 3B shows that siRNA reduction
of FXR1 also increases the abundance of inflammatory proteins
as well as HuR in TNFa-stimulated human VSMCs. As FXR1Reports 24, 1176–1189, July 31, 2018 1179
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knockdown increased inflammatory transcripts, we reasoned
that FXR1 overexpression would reduce abundance of inflam-
matory mRNA and protein. Adenoviral overexpression of FXR1
decreases the abundance of inflammatory mRNA (Figure 3C)
and protein (Figure 3D) in a dose-dependent fashion compared
with AdGFP control. The siRNA knockdown and overexpression
data are complementary and strongly suggest that FXR1 expres-
sionmay regulate abundance of inflammatory proteins as well as
HuR in VSMCs.
FMR1 family members are putative RBPs (Adinolfi et al., 1999),
and we next determined whether modulation of FXR1 would
affect mRNA stability. Using the transcription inhibitor actino-
mycin D in TNFa-stimulated VSMCs, we determined that the
mRNA stability of ARE-containing transcripts IL-1 b, ICAM1,
and HuR is significantly increased when FXR1 is knocked down
and, importantly, significantly decreased when FXR1 is overex-
pressed (Figures 4A and 4B). The mRNA stability of peroxisome
proliferator-activated receptor alpha (PPARa), the expression of
which is not regulated by AREs in its 30 UTR, was not affected
by FXR1 knockdown or overexpression, demonstrating target
transcript specificity for FXR1 activity. Of particular importance
was the finding that FXR1 appears to have a reciprocal relation-
ship with HuR abundance, suggesting important, possibly
competitive roles for these proteins in regulation of mRNA stabil-
ity. Together, these results suggest a previously unrecognized
function for FXR1 in regulation of mRNA stability and subsequent
abundance of pro-inflammatory proteins.
FXR1 Regulates VSMC Proliferation and Inflammation
through Paracrine Signaling
Maladaptive VSMC proliferation is a hallmark of several vascular
pathologies and is driven by inflammatory gene expression
(Hansson and Libby, 2006; Libby, 2002; Libby et al., 2014;
Ross, 1999). Knockdown of FXR1 in hVSMCs significantly
increased cell proliferation compared to scrambled control cells
(Figure 5A). Concordantly, VSMC proliferation was significantly
decreased in a manner inversely proportional with FXR1 expres-
sion, confirming that FXR1 can regulate VSMC proliferation
(Figure 5B).
VSMC paracrine signaling is also a characteristic of many
vascular diseases. Since FXR1 appeared to regulate the abun-
dance of cytokines, it was important to determine whether this
participated in paracrine signaling. First, serum-starved VSMCs
were stimulated with conditioned media collected from VSMCsFigure 3. FXR1 Regulates Abundance of Pro-inflammatory mRNA and
(A) FXR1 knockdown increasesmRNA abundance of inflammatorymediators in VS
serum starved, and then stimulated with TNFa for 4 hr to inducemRNA expression
are expressed as mean ± SEM; the experiment was performed in triplicate. Data
(B) FXR1 knockdown increases protein abundance of inflammatory mediators in
and stimulated with TNFa for 24 hr, and proteins were identified by western blot
periments.
(C) Overexpression of FXR1 reduces abundance of pro-inflammatory mRNA and
AdGFP, serum starved, and then stimulated with TNFa for 4 hr to induce mRN
expression. Data are expressed as mean ± SEM; the experiment was performe
experiments.
(D) FXR1 overexpression increases protein abundance of inflammatory mediato
above and stimulated with TNFa for 24 hr, and proteins were identified by weste
experiments.
*p < 0.05; **p < 0.01; ***p < 0.001.transfected with FXR1 siRNA or scrambled controls for 4 hr;
then, inflammatory transcript mRNA was quantitated. Figure 5C
shows that hVSMCs treatedwith FXR1 siRNA knockdown condi-
tioned media had increased inflammatory gene expression
compared to scrambled control.
Next, using conditioned media from scrambled control or
FXR1 siRNA knockdown VSMCs, we performed a proliferation
assay to demonstrate the autocrine and paracrine effects on
cell growth (Figure 5D). hVSMCs treated with FXR1 siRNA condi-
tioned media had significantly increased proliferation compared
to scrambled media control. These data suggest that the reduc-
tion of FXR1 results in increased cytokine production that has
potential autocrine and paracrine effects on other hVSMCs.
FXR1 Binds RNA via Canonical ARE and Non-ARE
Sequences
Various complementary methods were used to determine
whether FXR1 binds mRNA. First, glutathione S-transferase
(GST) and human GST-FXR1 fusion proteins were used in RNA
EMSAs (cRNA EMSAs) with a biotinylated probe consisting of
a 50-bp region of the human TNFa 30 UTR (position 1,333–
1,380). The addition of recombinant FXR1 to this probe sug-
gested that it bound to RNA (Figure 6A). The AUUUA monomer
(as negative control probe) did not form a complex with FXR1.
Interaction specificity was demonstrated by super-shift of the
FXR1-probe complex by the addition of anti-FXR1 antibody (Fig-
ure 6B). FXR1 binding affinity for this region was calculated, and,
in our hands, FXR1 has similar affinity to the TNFa probe as HuR
(Figures S2A and S2B).
To determine the site or sites on the TNFa 30 UTR recognized
by FXR1, four probes representing different regions of the 50-bp
TNFa 30 UTR (probe A) were synthesized; a 25-mer of (AUUUA)5
(probe B), a 27-mer of (UUAUUUAUU)3 (probe C), a 36-mer of
(CUUGUGAUU)4 (probe D), and a 40-mer of (CAGAGAUGAA)4
(probe E), were added to the cRNA EMSAs to compete with
the biotinylated 50-bp TNFa 30 UTR probe. The GST negative
control protein did not interact with any probes (Figures S3A
and S3B). FXR1 binding with various amounts of cold competitor
probes was performed to determine probe input concentrations
(Figures S4A and S4B). Figure 6C shows that probes B and C,
which contained recognized AREs, were capable of competing
with the full-length probe for FXR1 binding and nearly ablated
the gel shift. Interestingly, probe D, which does not contain aProteins in VSMCs
MCs. hVSMCswere transfectedwith FXR1 siRNA or scrambled control siRNA,
that was quantitated by qRT-PCR and normalized to GAPDH expression. Data
shown are representative of 3 independently performed experiments.
VSMCs. Cell extracts were prepared from VSMCs treated as described above
analysis. Image shown is representative from 3 independently performed ex-
proteins. hVSMCs were transduced with 100 MOI of adeno-FXR1 (AdFXR1) or
A expression that was quantitated by qRT-PCR and normalized to GAPDH
d in triplicate. Data shown are representative of 3 independently performed
rs in VSMCs. Cell extracts were prepared from VSMCs treated as described
rn blot analysis. Image shown is representative of 3 independently performed
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Figure 4. FXR1 Regulates mRNA Stability of Pro-inflammatory mRNA
(A) FXR1 knockdown increases inflammatory mRNA stability. hVSMCs were transfected with FXR1 siRNA or scrambled control siRNA, serum starved, and
stimulated with TNFa for 4 hr, at which point actinomycin D (10 ng/mL) was added to halt transcription. RNA was isolated at indicated times post-addition of
actinomycin D, and mRNA abundance was quantitated by qRT-PCR. Percent mRNA remaining was determined by normalizing each time point to beta-2-mi-
croglobulin (B2M). Data are expressed as mean ± SEM; the experiment was performed in triplicate. Data shown are representative of 3 independently performed
experiments.
(B) FXR1 overexpression reduces inflammatorymRNA stability. hVSMCswere transduced with adeno-FXR1 and adeno-GFP, serum starved, and stimulated with
TNFa for 4 hr, at which point actinomycin D (10 ng/mL) was added. RNA was isolated at the various time points post-addition of actinomycin D, and mRNA
abundancewas quantitated by qRT-PCR. Percent mRNA remaining was determined by normalizing each time point to B2M. Data are expressed asmean ±SEM;
the experiment was performed in triplicate. Data shown are representative of 3 independently performed experiments. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 5. FXR1 Regulates VSMC Proliferation
(A) hVSMCs transfected with FXR1 siRNA or scram-
bled control siRNA were seeded at 10,000 cells per
well and counted at days 3 and 6.
(B) hVSMCs were transduced with 100 MOI of adeno-
FXR1 or AdGFP, seeded at 10,000 cells per well, and
counted at days 3 and 6. Data are expressed as
mean ± SEM; the experiment was performed in tripli-
cate. Data shown are representative of 3 indepen-
dently performed experiments.
(C) Conditioned media from VSMCs in which FXR1 is
deleted can induce inflammatory and proliferative re-
sponses from naive VSMCs. hVSMCs were trans-
fected with scrambled control or FXR1 siRNA and
washed, and media were collected after 48 hr.
Conditioned media from each of these groups was
added to serum-starved hVSMCs for 4 hr, RNA was
isolated and reverse-transcribed for qRT-PCR anal-
ysis. #p < 0.07.
(D) HVSMCs were seeded at 20,000 cells per well in
FXR1 siRNA-conditioned media or scrambled control
media. Cells were counted at days 3 and 5. Data are
expressed as mean ± SEM; the experiment was per-
formed in triplicate. Data shown are representative of 3
independently performed experiments.
*p < 0.05; **p < 0.01; ***p < 0.001.canonical ARE, also successfully competed with the full-length
TNFa 30 UTR for FXR1 binding but did not compete with the
full-length probe for HuR, suggesting an additional, previously
unrecognized region on the TNFa 30 UTR recognized by FXR1.
These results were quantified using densitometry as a percent-
age of GST-protein bound to probe A (Figure 6C, lower panel).
An additional binding element termed the G quadruplex has
been implicated as a binding site for FXR1 (Bechara et al.,
2007). Using this element as a cold competitor to the biotinylated
TNFa 30 UTR probe, we found that the G quadruplex was able to
bind FXR1 (Figures S4C and S4D). Using RNA immunoprecipita-
tion (RIP), we determined whether FXR1 directly binds RNAs that
were shown to be regulated by FXR1. VSMCs were transduced
with FLAG-tagged adeno-FXR1, serum starved for 48 hr, and
then stimulated with TNFa for 8 hr. Figure 6D shows that several
transcripts were identified as interacting with FXR1 compared to
immunoglobulin G (IgG) control antibody. Importantly, mRNA
transcripts not regulated by AREs in 30 UTR such as PPARaCwere not amplified. It was possible that
FXR1 could compete with HuR for occu-
pancy on 30 UTR of transcripts that con-
tained these regions. A constitutively driven
luciferase reporter representing the TNFa 30
UTR and containing ARE tandem repeats
was transfected into HEK cells and also
transduced with plasmid encoding FXR1
cDNA or a control empty-vector plasmid.
Figure 6E shows that FXR1 reduced lucif-
erase activity, suggesting that FXR1 may
compete with HuR for ARE occupancy. We
also used an adenovirus expressing the
TNFa 30 UTR luciferase construct to perform
the experiment in hVSMCs. Adeno-FXR1 and AdHuR were co-
transduced with the adeno-expression TNFa 30 UTR luciferase,
as well as an AdGFP for control. Figure 6F demonstrates that,
in hVSMCs, FXR1 overexpression reduced TNFa 30 UTR lucif-
erase activity, while HuR was able to increase it, supporting
the concept that FXR1 is a negative regulator of inflammatory
transcripts.
IL-19 Induces FXR1 Expression in VSMCs
IL-19 is anti-proliferative for VSMCs and reduces inflammatory
transcript mRNA stability (Tian et al., 2008). Stimulation of
VSMCs with IL-19 significantly induces FXR1 mRNA and protein
expression (Figures 7A–7C). Long-term treatment of VSMCs
with IL-19 also reduces HuR protein abundance (Cuneo et al.,
2010; Ellison et al., 2013). To determine whether FXR1 mediated
the IL-19 decrease in HuR abundance, VSMCs were transfected
with FXR1 siRNA or scrambled control siRNA and serum
starved. VSMCs were then treated with IL-19 for various timeell Reports 24, 1176–1189, July 31, 2018 1183
Figure 6. FXR1 Binds mRNA
(A) RNA EMSA. Biotinylated RNA probes containing a scrambled control, a 50-mer of human TNFa 30 UTR, or (AUUUA)monomer were incubated with GST or GST-
FXR1 and membrane blotted to demonstrate a shift indicating a protein-RNA complex.
(B) GST or FXR1 antibodywas added to the EMSA reaction; supershift of the complex demonstrates specificity. Image shown is representative of 3 independently
performed experiments.
(C) FXR1 binds ARE and a novel element. Non-biotinylated probes consisting of a 25-mer of (AUUUA)5, a 27-mer of (UUAUUUAUU)3, a 36-mer of (CUUGU
GAUU)4, and a 40-mer of (CAGAGAUGAA)4 (40 bases) were added to the reaction prior to the addition of the biotinylated TNFa 50-mer, and RNA EMSA was
performed usingGST-FXR1 andGST-HuR. Densitometry of protein-probe complex was calculated as a percentage of binding to Probe A for both GST-FXR1 and
GST-HuR. Image shown is representative of 3 independently performed experiments. Densitometry was calculated from at least 3 independently performed
experiments.
(legend continued on next page)
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Figure 7. Anti-inflammatory Cytokine IL-19 Induces Expression of FXR1
(A) IL-19 induces FXR1 mRNA. hVSMCs were serum starved for 48 hr and then treated with IL-19 for the times indicated, and FXR1 mRNA was quantitated by
qRT-PCR normalized to GAPDH.
(B) IL-19 induces FXR1 protein expression. hVSMCs were treated as described in (A), and FXR1 protein was detected by western blot analysis.
(C) Densiometric analysis of FXR1 protein expression in IL-19-treated VSMCs normalized to GAPDH. Image shown is representative of 3 independently per-
formed experiments. Densitometry was calculated from at least 3 independently performed experiments.
(D) FXR1 mediates IL-19 reduction in HuR protein abundance. VSMCs were transfected with FXR1 siRNA or scrambled control siRNA and treated with IL-19 for
the times indicated, and extracts were blotted to detect FXR1, HuR, and GAPDH proteins.
(E) IL-19 reduces HuR mRNA stability. HVSMCs were unstimulated or treated with IL-19 for 16 hr prior to the addition of actinomycin D, and HuR mRNA
abundance was quantitated by qRT-PCR. Percent mRNA remaining was determined by normalizing each time point to B2M. Data are expressed asmean ±SEM;
the experiment was performed in triplicate. Data shown are representative of 3 independently performed experiments.
(F) hVSMCswere transfected with FXR1 siRNA or scrambled control prior to treatment with IL-19 for 16 hr. Actinomycin Dwas added, and HuRmRNA abundance
was quantitated by qRT-PCR. Percent mRNA remaining was determined by normalizing each time point to B2M. Data are expressed as mean ± SEM; the
experiment was performed in triplicate. Data shown are representative of 3 independently performed experiments.
*p < 0.05; **p < 0.01; ***p < 0.001.points, and cell extracts were used for western blot analysis (Fig-
ure 7D). As reported, IL-19 treatment can reduce HuR protein
abundance; however, in the absence of FXR1, IL-19 is unable
to reduce HuR, indicating that IL-19 reduction of HuR requires
FXR1. To further dissect the mechanism by which IL-19 reduces
HuR abundance, we determined that IL-19 is able to reduce HuR
mRNA stability in hVSMCs following actinomycin D treatment
(Figure 7E). However, in the absence of FXR1, IL-19 was unable
to reduce HuR mRNA stability compared to scrambled control,
suggesting that FXR1 is necessary for IL-19-induced destabiliza-
tion of HuR (Figure 7F). Since FXR1 is induced by IL-19 and is
necessary for IL-19 destabilization and reduction of HuR, we(D) RNA immunoprecipitation. VSMCs were transduced with FLAG-tagged aden
complexes were immunoprecipitated with FLAG or IgG control beads. PPARa, l
(E) The TNFa 30 UTR luciferase construct was co-transfected into HEK293 cells w
before harvesting. Luminescence was measured using an Infinite M1000 Pro pla
(F) Adenoviral expression of TNFa 30 UTR luciferase construct was co-transduc
graphed as a percentage of luciferase AdGFP. Data are expressed asmean ± SEM
3 independently performed experiments.
*p < 0.05, **p < 0.01, ***p < 0.001, #p < 0.07. See also Figures S2, S3, and S4.conclude that FXR1 expression is a negative compensatory,
counter-regulatory mechanism used by VSMCs to respond to
and dampen inflammation.
DISCUSSION
The major findings of this study are that FXR1 expression in
VSMCs reduces mRNA stability and the abundance of pro-
inflammatory proteins, is induced by the anti-inflammatory cyto-
kine IL-19, and acts as an effector of IL-19 anti-inflammatory
activity in VSMCs. This has important implications for the resolu-
tion of inflammation in general, and in the attenuation of severityo-FXR1, serum starved for 48 hr, and then stimulated with TNFa. RNA-protein
acking AREs in its 30 UTR, was not amplified.
ith either a vector control or pFXR1. The cells were seeded in triplicate for 48 hr
te reader and graphed as a percentage of GFP luciferase control.
ed into hVSMCs with AdGFP, adeno-FXR1, or AdHuR, and the results were
; the experiment was performed in triplicate. Data shown are representative of
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of vascular inflammatory syndromes such as atherosclerosis,
restenosis, and allograft vasculopathy in particular. Investigation
into vascular inflammation primarily focuses on the role of im-
mune cells, but in this study, we show that a non-immune cell
can respond to anti-inflammatory stimuli through post-transcrip-
tional mechanisms. Most inflammatory cytokines contain
conserved or semi-conserved AU-rich elements in their 30 UTR
(Peng et al., 1996), imparting target specificity to allow the cell
to fine-tunemRNA abundance and translation for rapid response
to inflammation (Schoenberg and Maquat, 2012). An essential
regulatory protein involved in this process is HuR (Peng et al.,
1996; Schoenberg and Maquat, 2012), and proteins and path-
ways that regulate HuR may be key targets in the regulation of
inflammation. We previously reported that IL-19 reduces HuR
activity in VSMCs, leading to a decrease in mRNA stability in a
HuR-mediated but un-characterized mechanism. A goal of this
study was to identify proteins that would interact with HuR and
regulate its activity.
An unbiased pull-down experiment using FLAG-tagged HuR
and LC-MS/MS to identify protein constituents of HuR com-
plexes in VSMCs uncovered a number of interesting proteins
recognized to participate in various aspects of mRNA process-
ing. Studies have extensively characterized the messenger
ribonucleoprotein (mRNP) complexes that form to regulate
mRNA transcripts and translation, while the profile of proteins
known to directly interact with HuR, particularly in an inflamma-
tion responsive fashion, is more limited. Interaction with one
candidate identified in our analysis, FXR1, was validated by
co-immunoprecipitation and cellular co-localization assays,
validating the LC-MS/MS result, and is a previously unrecog-
nized observation of this study. FXR1 is an autosomal homolog
of FMR protein, the prototypical and best studied member of
the FXR (fragile X-related) family of neuronal proteins (Bardoni
et al., 2001). The vast majority of work on FMR1-, FXR1-, and
FXR-related proteins are performed in neurons and focuses
on their role in cognitive ability; nothing is known about this
family of proteins in VSMCs or vascular pathophysiology.
FXR1 is the only fragile X protein family member significantly
expressed in muscle cells (Garnon et al., 2005; Mientjes
et al., 2004) and has been described as the ‘‘muscle homo-
logue’’ of the FMR family (Mientjes et al., 2004). In addition,
our data suggest that FXR1 is upregulated in VSMCs specif-
ically in inflamed regions of arteries from disease states. For
these reasons, we focused on the role of FXR1 in VSMCs for
further study.
HuR is characterized as an mRNA-stabilizing RBP, while
FXR1 function is less understood and appears to be cell type
specific. When we knocked down FXR1 using siRNA in
TNFa-stimulated hVSMCs, we were initially surprised to
observe that inflammatory transcripts were increased at both
the transcript and protein levels. Knockdown of FXR1 in
VSMCs in the presence of actinomycin D demonstrated signif-
icantly increased mRNA stability of several pro-inflammatory
transcripts, in direct contrast to a study in macrophages
showing that absence of FXR1 did not affect TNFa mRNA
half-life (Garnon et al., 2005). Stability of PPARa mRNA, a tran-
script not regulated by AREs in its 30 UTR, was unaffected by
FXR1 knockdown. RBPs have the ability to be cell type specific1186 Cell Reports 24, 1176–1189, July 31, 2018in their function, especially those that have cell-specific expres-
sion (Musunuru, 2003). Since knockdown of FXR1 increased in-
flammatory transcripts, we reasoned that FXR1 overexpression
would reduce the abundance of inflammatory mRNA and pro-
tein. Indeed, adenoviral overexpression of FXR1 significantly
decreased the abundance of several inflammatory mRNAs
and proteins. Concordant with knockdown, overexpression
did not affect PPARa mRNA stability in any way. This study in-
dicates that FXR1 knockdown results in increased HuR protein
abundance mRNA stability, and overexpression results in the
opposite, suggesting a previously unrecognized mechanism
in regulation of pro-inflammatory transcripts. HuR abundance
is auto-regulated by a positive-feedback loop involving HuR
interaction with the 30 UTR of its own mRNA (Dai et al.,
2012). These authors suggested that HuR mRNA is destabilized
through an ARE-dependent but unidentified mechanism, which
we posit could be FXR1 interaction with the HuR 30 UTR. FXR1
knockdown also increased hVSMC proliferation, and FXR1
overexpression reduced hVSMC proliferation. This proliferative
effect may be due to a decrease in autocrine expression of cy-
tokines and growth factors, as VSMCs are known to proliferate
in an autocrine fashion. Concordantly, conditioned media from
FXR1 knockdown VSMCs increased inflammatory cytokine
expression and proliferation of naive VSMCs as well. FXR1
expression is critically important, so much so that FXR1
knockout mice are postnatally lethal (Mientjes et al., 2004),
and, in conjunction with its upregulation in injured arteries,
this supports a role for FXR1 in the maintenance of the quies-
cent VSMC phenotype. Overall, siRNA knockdown and overex-
pression data are complementary, and are associated with the
presence of AREs in transcript 30 UTR. These data strongly
suggest that, in VSMCs, FXR1 functions as an mRNA de-stabil-
ity factor to reduce inflammatory transcripts. In this regard,
FXR1 appears to function similarly to other destabilizing
RBPs, such as Tristetraprolin (TTP) and AUF1 (hnRNP D), which
function to alter the transcript stability of TNFa via AREs in the
30 UTR (Carballo et al., 1998). Because FXR1 expression is
enhanced in muscle; is induced by IL-19, an anti-inflammatory
stimulus; and can regulate inflammatory protein abundance in
VSMCs, FXR1 can potentially have key regulatory effects in
the modulation of vascular inflammatory diseases.
It was plausible that both FXR1 and HuR would bind the same
region in the 30 UTR. The addition of RNase A abrogated the
FXR1-HuR interaction, suggesting that the FXR1-HuR interac-
tion was indirect, a result of tethering by occupancy on the
same mRNA. This would also explain why we observed
increased FXR1-HuR interaction in TNFa-stimulated VSMCs,
as TNFa would induce expression of inflammation-inducible
transcripts with AREs in their 30 UTR, thus increasing the avail-
ability of transcripts for each protein to bind.
Many assumptions on the functions of FXR family members
are based on themuch better characterized FMR protein. Similar
to the better characterized FMR protein, FXR1 contains two KH
domains for RNA binding and anRGGbox, which is the preferred
binding domain of FMRP. Using regions of the TNFa 30 UTR, two
different but complementary methods were used to determine
that FXR1 binds mRNA and also validate that FXR1 tethers to
mRNA. FXR1 mRNA recognition sites have not been identified.
Using biotinylated cRNA pentameric probes representing
various sequences of this region as cold competitors, we identi-
fied canonical AU-rich elements as putative FXR1 binding sites,
as well as a previously undescribed element comprising the
sequence CUUGUGAUU. This corroborates experiments
showing that FXR1 modulation affected the stability of tran-
scripts that contained AREs in their 30 UTR. FXR1 recognition
of AREs also suggested that FXR1 could compete with HuR for
occupancy on AREs of inflammatory transcripts. FXR1 also
bound the G quadruplex complex, but because this region is
not present in the TNFa 30 UTR 50-mer probe, it does not exclude
the possibility of competition for a common binding site with HuR
on inflammatory transcripts.
RBPs such as HuR can block endonucleolytic cleavage sites
to prevent mRNA degradation and, therefore, increase mRNA
stability (Hollams et al., 2002). FXR1 reduced luciferase activity
in a reporter driven by the TNFa 30 UTR, further suggesting that
FXR1 may act as an mRNA de-stability protein by competing
with HuR, which can also bind and stabilize the same region.
Competition of FXR1 for HuR binding sites on the 30 UTR as a
mechanism to dampen the inflammatory response of select tran-
scripts has not previously been reported. Considering FXR1’s
reciprocal relationship with HuR, FXR1 could potentially
compete with HuR for binding to its own 30 UTR, reducing HuR
mRNA stability, decreasing HuRmRNA abundance, and thus re-
pressing pro-inflammatory gene protein expression. While this
study does not rule out the possibility that FXR1 binds to tran-
scripts and targets them for degradation independently of
HuR, it does strongly suggest that FXR1 has the potential to
oppose HuR and thus act as an mRNA de-stability factor.
Many factors involved in RNA stability, as well as transcriptional
and translational regulatory proteins, localize in discrete cyto-
plasmic phase-dense stress granules. HuR and other RBPs,
such as TTP and TIA-1, have been reported to localize to stress
granules (Kedersha et al., 2008). The co-localization of FXR1with
HuR in cytoplasmic stress granules further points to an important
role for these proteins in the post-transcriptional regulation of in-
flammatory mediators and resolution of the cellular inflammatory
response.
IL-19 decreases atherosclerosis and vascular restenosis (Elli-
son et al., 2013, 2014) and reduces HuR protein abundance, in-
flammatory mRNA stability, and abundance of pro-inflammatory
proteins in VSMCs (Cuneo et al., 2010; Tian et al., 2008). While
some RBPs can be induced by pro-inflammatory stimuli, very lit-
tle is known about the anti-inflammatory effects of RBPs as a
countervailing mechanism to resolve inflammatory processes.
In this report, we show that stimulation of hVSMCs with IL-19 in-
creases the expression of FXR1, placing FXR1 expression as
part of the IL-19 anti-inflammatory pathway. We also demon-
strate that FXR1 is required for HuR reduction and destabilization
by IL-19, further placing FXR1 as an effector protein and part of
the anti-inflammatory pathway of IL-19. Our working hypothesis
is that FXR1 expression in VSMCs is a counter-regulatory mech-
anism used by VSMCs to respond to and dampen vascular
inflammation.
This study describes that FXR1, a muscle-enhanced protein
best known as a homolog of the neuronal protein FMR, can be
induced in VSMCs by anti-inflammatory stimuli. FXR1 can bindto mRNA at AREs and participate in inflammatory transcript
processing by competing with HuR, resulting in a reduction in in-
flammatory mRNA stability.
The balance of RBPs in homeostasis and pathological
conditions has not been well characterized, but, based on the
opposing functions of HuR and FXR1 and the shared repertoire
of transcripts they regulate, we posit that an equilibrium between
stabilizing and destabilizing RBPs is critical to the maintenance
of inflammatory and proliferative transcripts, particularly in
VSMCs, a non-immune cell type. This work implicates FXR1 as
a molecular mediator to resolve vascular inflammation.
EXPERIMENTAL PROCEDURES
VSMC Culture
Primary human coronary artery VSMCs were obtained as cryopreserved sec-
ondary culture from Lonza (Allendale, NJ, USA) and maintained as we
described previously (Gabunia et al., 2017; Tian et al., 2008). Cells were
used from passages 3–5.
Immunohistochemistry
Ligated mouse carotid arteries, plaque from LDLR/ mice, and human coro-
nary arteries were collected as part of studies described previously (Ellison
et al., 2013, 2014) and are described in detail in the Supplemental Information
section.
LC-MS/MS
LC-MS/MS analysis was performed as described previously (Haines et al.,
2012) and are provided in detail in the Supplemental Information section.
Transfection, siRNA Knockdown and Overexpression, and
Luciferase
Gene silencing was performed using ON-TARGET plus SMARTpool FXR1
siRNA, which contains a mixture of four siRNAs that target human FXR1
(10 nM) purchased from Dharmacon (Lafayette, CO, USA), as we have
described previously (Cuneo et al., 2010; Gabunia et al., 2016), and that are
described in detail in the Supplemental Information section.
For conditioned media transfer experiments, media was collected from
hVSMCs transfected with scrambled control or FXR1 siRNA. Conditioned me-
dia from each of these groups was added to serum-starved hVSMCs for 4 hr,
and RNAwas isolated and reverse-transcribed for qRT-PCR analysis. For pro-
liferation, hVSMCs were seeded at 20,000 cells per well in FXR1 siRNA condi-
tioned media or scrambled control media. Cells were counted at days 3 and 5
on a Cellometer Auto T4 Bright Field Cell Counter (Nexcelom Bioscience, Law-
rence, MA, USA) (*p < 0.05, **p < 0.01, or ***p < 0.001).
RNA Extraction and qRT-PCR
VSMCs were serum starved in 0.1% fetal calf serum (FCS) for 48 hr and then
stimulated with 10 ng/mL TNFa for the indicated times. RNA from cultured
VSMCswas isolated and reverse transcribed into cDNA, aswe have described
previously, and target genes were amplified using an Applied Biosystems Ste-
pOne Plus Real-Time PCRSystem, as we described previously (Gabunia et al.,
2016, 2017), and are described in detail in the Supplemental Information
section.
Western Blotting and Protein Determination
Human VSMC extracts were prepared as described (Ellison et al., 2013; En-
gland et al., 2013; Gabunia et al., 2017). Membranes were incubated with a
1:5,000–9,000 dilution of primary antibody and a 1:5,000 dilution of secondary
antibody. IL-1b, ICAM-1, FXR1, GAPDH, and HuR were from Santa Cruz
Biotechnology (Dallas, TX, USA). HuR and FXR1 were from Abcam. Glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) was from Cell Signaling Tech-
nology (Danvers, MA, USA). Reactive proteins were visualized using enhanced
chemiluminescence (Amersham, Piscataway, NJ, USA), according to theman-
ufacturer’s instructions. Relative intensity of bands was normalized to GAPDH,Cell Reports 24, 1176–1189, July 31, 2018 1187
and quantitated by scanning image analysis and the ImageJ densitometry
program.
cRNA EMSA
FXR1 and GST control fusion proteins were generated using a GenScript kit
for GST fusion protein purification, purified from E. coli lysates, and then
separated using a protease kit from GE Life Sciences PreScission Protease
(Piscataway, NJ, USA). Purified proteins (2 mM) were incubated with bio-
tinylated probe (100 pM) consisting of nt 1,333–1,380 in the TNFa 30 UTR
(50CUUGUGAUUAUUUAUUAUUUAUUUAUUAUUUAUUUAUUUACAGAGA
UGAA-30) in binding buffer and glycerol. The binding reaction was run on a
5% precast polyacrylamide gel (Bio-Rad, Hercules, CA, USA). The gel was
transferred to nylon membrane, cross-linked with UV light, and blocked.
The membrane was then incubated with streptavidin antibody and devel-
oped using chemiluminescence. Five non-biotinylated probes were used
in a cold competition experiment: (UUAUUUAUU)3, (AUUUA)5, (CUUGU
GAUU)4, (CAGAGAUGAA)4, and scrambled control (AUCG)5 were incubated
with GST-protein and binding buffer and/or glycerol for 30 min before the
addition of the biotinylated TNFa. In Figures S3C and S3D, the G quadruplex
probe (GGGGUGGGUGGGGGGCAGUGGGGGCUGGGCGGGGGG) was
used as a cold competitor to TNFa using the same experimental setup as
previously described. Binding affinity was calculated as described previ-
ously (Bechara et al., 2007).
Co-Immunoprecipitation and RIP
For co-immunoprecipitation (coIP), hVSMCs were washed three times in PBS
and scraped off the dish into a conical tube and centrifuged to form a cell
pellet. hVSMC extracts were lysed in lysis buffer (50 mM HEPES [pH 7.5],
70 mM KOAc, 5 mM Mg(OAc)2 in 0.1 M Tris-HCl [pH 8.5] with 0.1 g n-do-
decyl-B-maltoside and protease inhibitor) and incubated on a nutator at 4C
for 30 min. Cells were centrifuged at 16,600 rpm for 15 min. Anti-FLAG M2 af-
finity beads (Sigma-Aldrich, St. Louis, MO, USA) were washed and added to
each sample and incubated on the nutator overnight at 4C. The samples
were centrifuged at 13,000 rpm and washed three times in lysis buffer. Sample
buffer was added, and samples were boiled and frozen or used for western
blotting. For RIP, hVSMCs were transduced with adeno-FXR1 prior to serum
starvation for 48 hr. Cells were treated with TNFa for 8 hr and lysed in IP buffer
with RNase inhibitor. Samples were divided, and half were incubated with IgG
control beads or FLAG-conjugated beads for 4 hr at 25C. The beads were
then centrifuged and washed 53 in IP buffer. TRIzol was added to the pelleted
beads, and RNA was extracted and reverse transcribed to cDNA. We per-
formed qRT-PCR for the transcripts indicated.
Statistical Analysis
Results are expressed asmean±SEM.Differences between groupswere eval-
uated with the use of Student’s t test, or ANOVA, where appropriate, and per-
formed using Prism software (GraphPad, La Jolla, CA, USA). Differences were
considered significant when p < 0.05. All experiments using cultured cells were
performed in triplicate, from at least three independent experiments. Quantifi-
cationsofwesternblot and immunofluorescence imageswereperformedusing
ImageJ software from at least three independent experiments.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.07.002.
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